Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO, May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, across ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores ...

Halozyme Therapeutics, Inc. (HALO) reported first-quarter 2024 adjusted earnings of 79 cents per share, which surpassed the Zacks Consensus Estimate of 69 cents. The company had recorded earnings of 47 cents per share in the year-ago period.Total revenues increased 21% year over year to $195.9 million in the first quarter. The top line was driven by higher royalty payments from J&J (JNJ) for subcutaneous Darzalex (daratumumab) and Roche (RHHBY) for Phesgo, as well as increased milestone payments from collab ...

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: The Citizens JMP Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, May 14, 2024 Presentation Time: 7:00 a.m. PT / 10:00 a.m. ET Location: New York, NY   Event: Benchmark 202 ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Jessica Fye - J.P. Morgan Michael DiFiore - Evercore ISI Mohit Bansal - Wells Fargo Corinne Johnson - Goldman Sachs Jason Butler - Citizens JMP Brendan Smith - ...

For the quarter ended March 2024, Halozyme Therapeutics (HALO) reported revenue of $195.88 million, up 20.8% over the same period last year. EPS came in at $0.79, compared to $0.47 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $201.72 million, representing a surprise of -2.90%. The company delivered an EPS surprise of +14.49%, with the consensus EPS estimate being $0.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.49%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.82 per share when it actually produced earnings of $0.82, delivering no surprise.Over the last four quarter ...

✓ 1Q 2024 marks 15th consecutive quarter of >15% YOY royalty growth • Ocrelizumab SC (EU), mid-2024 ≫ | --- | --- | --- | |--------------------------|--------------|------------| | 1Q 2024 Phesgo ® Sales | Sales (CHFm) | Growth CER | | TOTAL | 338 | 70% | | US | 126 | 36% | | EU | 169 | 55% | | Japan | 19 | NA | | International | 74 | 165% | 8 2 Product Approvals Total DARZALEX® Sales IV+SC ($B) 1 85% of patients preferred Phesgo® for subcutaneous administration over the intravenous formulation of Perjeta a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 _______________________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...